Update: 01.02.2021
Last week: 3 week 2022 (17.01.2022 - 23.01.2022)
Last full month: Dec 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | ||||||||
| WoW | 2 483 | -1.1% | 54.1% | -1.5 | 1 087 983 | -2.0% | 81.6% | -1.1 |
| MoM | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| YTD | 6 545 | 7.4% | 52.3% | -6 | 2 871 388 | 37.3% | 80.4% | -0.4 |
| MAT | 118 060 | -23.4% | 55.3% | -6.4 | 46 390 921 | 1.0% | 80.2% | -0.5 |
| CAPSICAM | ||||||||
| WoW | 23 958 | 3.3% | 3.5% | -0.1 | 9 834 753 | 3.3% | 3.7% | -0.2 |
| MoM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| YTD | 65 171 | -6.0% | 3.5% | 0.1 | 26 769 946 | -8.9% | 3.9% | -0.3 |
| MAT | 1 060 992 | -19.6% | 3.2% | -0.2 | 436 350 316 | -8.4% | 3.5% | -0.2 |
| MILDRONATE | ||||||||
| WoW | 107 772 | 4.5% | 21.5% | -1.8 | 44 033 457 | 6.6% | 18.9% | -1.3 |
| MoM | 417 135 | -7.8% | 22.5% | 0.6 | 162 253 267 | -6.5% | 19.0% | 0.2 |
| YTD | 282 807 | 11.9% | 17.0% | 1.2 | 113 571 455 | 2.8% | 15.1% | -0.2 |
| MAT | 4 825 697 | 10.9% | 17.3% | 3.1 | 1 936 652 913 | 14.3% | 15.4% | 2.4 |
| SULFARGIN | ||||||||
| WoW | 3 401 | 0.6% | 1.0% | 0 | 1 659 266 | 0.2% | 1.4% | 0 |
| MoM | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| YTD | 9 070 | -2.4% | 0.9% | 0.1 | 4 457 744 | 3.4% | 1.3% | 0.2 |
| MAT | 163 928 | -21.8% | 0.8% | -0.1 | 79 904 437 | -9.2% | 1.2% | -0.1 |
| VIPROSAL | ||||||||
| WoW | 28 987 | 6.3% | 4.2% | 0 | 11 389 020 | 6.0% | 4.3% | -0.1 |
| MoM | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| YTD | 79 087 | 28.1% | 4.3% | 1.2 | 31 135 605 | 29.5% | 4.5% | 1.1 |
| MAT | 1 260 852 | -10.8% | 3.8% | 0.1 | 478 375 034 | -2.0% | 3.8% | 0 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 2 483 | -1.1% | 54.1% | -1.5 | 1 087 983 | -2.0% | 81.6% | -1.1 |
| CAPSICAM | 23 958 | 3.3% | 3.5% | -0.1 | 9 834 753 | 3.3% | 3.7% | -0.2 |
| MILDRONATE | 107 772 | 4.5% | 21.5% | -1.8 | 44 033 457 | 6.6% | 18.9% | -1.3 |
| SULFARGIN | 3 401 | 0.6% | 1.0% | 0 | 1 659 266 | 0.2% | 1.4% | 0 |
| VIPROSAL | 28 987 | 6.3% | 4.2% | 0 | 11 389 020 | 6.0% | 4.3% | -0.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| CAPSICAM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| MILDRONATE | 417 135 | -7.8% | 22.5% | 0.6 | 162 253 267 | -6.5% | 19.0% | 0.2 |
| SULFARGIN | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| VIPROSAL | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 6 545 | 7.4% | 52.3% | -6 | 2 871 388 | 37.3% | 80.4% | -0.4 |
| CAPSICAM | 65 171 | -6.0% | 3.5% | 0.1 | 26 769 946 | -8.9% | 3.9% | -0.3 |
| MILDRONATE | 282 807 | 11.9% | 17.0% | 1.2 | 113 571 455 | 2.8% | 15.1% | -0.2 |
| SULFARGIN | 9 070 | -2.4% | 0.9% | 0.1 | 4 457 744 | 3.4% | 1.3% | 0.2 |
| VIPROSAL | 79 087 | 28.1% | 4.3% | 1.2 | 31 135 605 | 29.5% | 4.5% | 1.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 118 060 | -23.4% | 55.3% | -6.4 | 46 390 921 | 1.0% | 80.2% | -0.5 |
| CAPSICAM | 1 060 992 | -19.6% | 3.2% | -0.2 | 436 350 316 | -8.4% | 3.5% | -0.2 |
| MILDRONATE | 4 825 697 | 10.9% | 17.3% | 3.1 | 1 936 652 913 | 14.3% | 15.4% | 2.4 |
| SULFARGIN | 163 928 | -21.8% | 0.8% | -0.1 | 79 904 437 | -9.2% | 1.2% | -0.1 |
| VIPROSAL | 1 260 852 | -10.8% | 3.8% | 0.1 | 478 375 034 | -2.0% | 3.8% | 0 |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs